Team Liquid parent group aXiomatic has raised $25 million in a Series B funding round led by Golden State Warriors executive board member Bruce Karsh, according to an April document filed with the ...
The oral factor XIa inhibitor milvexian is a promising option for preventing venous thromboembolism (VTE) while keeping bleeding risk low, according to the randomized AXIOMATIC-TKR trial. Presented in ...
Esports organizer Axiomatic Gaming raised $21 million April 18, according to Securities and Exchange Commission filings. The $21.5 million raised was part of a planned $25 million round. Axiomatic has ...
Addition of an oral factor XIa inhibitor to aspirin and clopidogrel vs. standard therapy for stroke prevention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback